ClinicalTrials.gg
Not yet recruitingNCT06117657Updated Nov 8, 2023

Safety and Efficacy Clinical Study of KL-HIV-Tri01 in the Treatment of HIV Infected Subjects

An Early Phase 1 interventional study of Low dose KL-HIV-Tri01 and Middle dose KL-HIV-Tri01 in HIV Infections, sponsored by Affiliated Hospital of Guangdong Medical University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Affiliated Hospital of Guangdong Medical University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of KL-HIV-Tri01 injection solution in HIV infected subjects treated with HAART.

Read the detailed description

This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of KL-HIV-Tri01 injection solution expressing triple targets antibodies with broad HIV-1 neutralizing activity in HIV-1 infected adults on anti-retroviral therapy (ARV). Nine subjects will be enrolled and administered with three different doses of KL-HIV-Tri01. Subjects will provide informed consent and then undergo screening assessments up to 1 month prior administration of KL-HIV-Tri01. All subjects will undergo 52 weeks safety observation and will be encouraged to enroll in an extension study to evaluate long- term safety of KL-HIV-Tri01 for total 5 years.

02

Conditions studied

  • HIV Infections

Browse trials for

03

In context

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's planned enrollment of 9 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

Affiliated Hospital of Guangdong Medical University is the lead sponsor of 12 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.18 (not inclusive) to 80 (inclusive) years of age, both male and female.

  1. Conform to the Chinese AIDS Diagnosis and Treatment Guidelines (2021), positive, and received HAART treatment for ≥ 3 months before enrollment.
  1. CD4+T cell count≥500 cells/μl.
  1. On a stable antiretroviral regimen before enrollment and viral load less than 40 copies/mL in two consecutive tests one year prior to enrollment.
  1. Willing to fully understand the purpose, nature, method, and potential adverse reactions that may occur during the discontinuation period of the experiment, voluntarily participate in this experiment and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
  2. Active viral infections, such as , , CMV, or other viruses that the investigator believes will affect clinical research.
  3. Any opportunistic infection in the past one year, such as tuberculosis, cryptococcosis, which is not cured after treatment.
  4. Currently treated with medications or .
  5. Previous receipt of vaccine, antibody or gene therapy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    KL-HIV-Tri01 injection solution

    Subjects will be dosed with three different dose of KL-HIV-Tri01 injection solution at 2.4x10\^11 vg/kg to 2.4x10\^12 vg/kg.

    Drug: Low dose KL-HIV-Tri01 · Drug: Middle dose KL-HIV-Tri01 · Drug: High dose KL-HIV-Tri01

Interventions

  • DrugKL001Studies of KL001KL001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.

    Also known as: rAAV vector

  • DrugKL001Studies of KL001KL001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.

    Also known as: rAAV vector

  • DrugKL001Studies of KL001KL001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.

    Also known as: rAAV vector

06

What researchers measure

Primary outcomes

  1. Number and severity of AEs and SAEs

    AEs and SAEs from the date of product administration will be recorded through the last study visit. The relationship between AEs and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol.

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

  2. Neutralizing Antibodies Against KL-HIV-Tri01 Capsid

    Anti-KL-HIV-Tri01 Capsid antibodies were analyzed by enzyme-linked immunosorbent assay (ELISA) using a vector-matched AAV capsid as the capture agent.

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

  3. Inhibitors of broadly neutralizing antibodies

    Inhibitors against broadly neutralizing antibodies expressed by KL-HIV-Tri01 were analyzed by enzyme-linked immunosorbent assay (ELISA) .

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

  4. Cells mediated immune response against capsids and bNabs

    Number of participants with T-cell response to AAV capsid and transgene products was planned to be reported.

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

Secondary outcomes

  1. Concentration and titer of serum neutralizing antibodies

    The serum concentration and titer of neutralizing antibodies produced by KL-HIV-Tri01 at specified time intervals for 52 weeks after dosing was determined

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

  2. CD4+T, CD8+T cell count

    The clinical effects of KL-HIV-Tri01 on CD4+T and CD8+T cell count were assessed. CD4+T and CD8+T Cell Count (cells/mL) shown as reported by the Clinical Center serology lab

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

  3. viral load

    The clinical effects of KL-HIV-Tri01 on viral load were assessed after interruption of HAART.

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

  4. Time to interrupt HAART treatment

    The duration of anti-HIV replication effection of the neutralizing antibodies produced by KL-HIV-Tri01were assessed after interruption of HAART.

    Time frame: Day 0 through 52 Weeks after KL-HIV-Tri01 administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Aug 2024, 9 months later.

Of 91 non-industry phase 1 interventional studies under HIV Infections, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 9 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 7, 2023
StartEst.
Nov 10, 2023
Primary completionEst.
Aug 20, 2024
CompletionEst.
Sep 10, 2025
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06117657
Lead sponsor
Affiliated Hospital of Guangdong Medical University
Responsible party
Honghua He (Associated chief physician, Affiliated Hospital of Guangdong Medical University) — Principal investigator
First posted
Nov 7, 2023
Start date
Nov 10, 2023 (estimated)
Primary completion
Aug 20, 2024 (estimated)
Completion
Sep 10, 2025 (estimated)
Last update
Nov 8, 2023

Study contacts

Honghua He, MD
Contact
192880@qq.com
+86 138 2822 9695
Honghua He, MD
principal investigator · Affiliated Hospital of Guangdong Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KL001

Start the discussion